Ideas
Beijing small caps froth warrants caution
Beijing Stock Exchange and small-cap valuations are around 90 times earnings, more than double Nasdaq levels, and regulators appear concerned about froth and leverage after a surge in small-cap trading; this makes the segment vulnerable to tighter margin financing.
Structural yen bear, tactical intervention risk
He remains a structural yen bear because Japan has a large debt pile it will ultimately monetize, keeping the yen weak over the long term; near fresh dollar-yen levels, intervention risk makes the trade more tactical but does not change the underlying bearish yen view.
Structural yen bear, tactical intervention risk
He remains a structural yen bear because Japan has a large debt pile it will ultimately monetize, keeping the yen weak over the long term; near fresh dollar-yen levels, intervention risk makes the trade more tactical but does not change the underlying bearish yen view.
Silver rally vulnerable to horrendous pullback
The silver rally is extraordinary and bonkers, with prices doubling since October and no fundamental explanation fully justifying the move; he expects a horrendous pullback at some point and is watching silver closely.
Prefer Hong Kong over mainland China stocks
He prefers Hong Kong stocks over mainland China stocks because Hong Kong is discounted, liquid, large and free of capital controls, and after years of underperformance it is early in a multi-year outperformance; mainland China stocks are no longer cheap, more opaque on earnings and harder to play.
Prefer Hong Kong over mainland China stocks
He prefers Hong Kong stocks over mainland China stocks because Hong Kong is discounted, liquid, large and free of capital controls, and after years of underperformance it is early in a multi-year outperformance; mainland China stocks are no longer cheap, more opaque on earnings and harder to play.
3SBio pipeline and Pfizer deal promising
3SBio has strong clinical data, multiple bispecific antibodies in Phase 1/2 trials and US FDA clinical approvals, plus a record Pfizer deal with $1.5 billion upfront and up to $4.8 billion in milestones; management expects busy business development and a promising 2-3 year outlook, with internationalization via Pfizer approvals.
Trip.com faces antitrust overhang
The Trip.com antitrust probe is not surprising given regulatory scrutiny of dominant platforms and comes ahead of peak Lunar New Year travel; the investigation could take months and lead to a cash fine, and if exclusivity practices are challenged Trip.com may have to loosen practices and its dominance could be less absolute under the common prosperity policy.
GLP-1 patent expiry pressures incumbents
Semaglutide/Ozempic/Wegovy patent expiry in March across China, India, Brazil and Canada opens the door to cheap regulated generics, with ten companies already filing in China; intense competition and a price war could drive prices as low as $5 per month in some countries and pressure Novo Nordisk and Eli Lilly to cut prices.
Cautiously optimistic on China A-shares
The margin-financing tightening is a mild signaling move to tame speculative momentum rather than derail the market; she remains cautiously optimistic on China A-shares, supported by liquidity reallocation from funds and term deposits into equities and strong insurance buying, while MSCI China earnings growth is projected at 7% with potential policy support later.
Hong Kong IPOs, strong CNY draw investors
Hong Kong is supported by a strong IPO market and continuous supply of high-quality companies, drawing global investors including those interested in cornerstone roles; a strong CNY also has a positive translation impact on earnings and revenue for foreign investors holding Chinese assets.
China AI, robotics, biotech drive earnings
She recommends following China's 15th Five-Year Plan National Growth Strategy and is a big fan of AI in China, robotics, automation, biotech and smart manufacturing because these sectors should deliver above-market-average earnings growth, which should be the key stock-picking differentiator.
China insurers offer yield, rally leverage
She likes the insurance sector because it offers attractive dividend yields of 3-5% and tends to perform better in a generally rising equity market, resonating with the broader China equity rally.
Alibaba AI app integrates ecosystem services
Alibaba is integrating Taobao, Alipay, travel, mapping, food delivery and other ecosystem services into its Qwen AI app to create a one-stop personal assistant; this is a major consumer-facing AI push that may solidify its competitive position versus Baidu and Tencent, though ByteDance and Tencent remain intense competitors.
Private credit quality is concerning
Private credit is not yet a major competitive threat to digital banks in consumer lending, but it is in corporate lending; the bigger concern is the quality of private credit, as deals banks deem unacceptable migrate to private-credit funds with different risk appetite.
TSMC earnings key AI demand read
TSMC's upcoming earnings are a pivotal AI-demand read, with expectations for around 20% revenue growth, record quarterly profit and gross margin of 59-61%, driven by AI spending and high utilization; investors are focused on 2026 guidance near $46 billion, CapEx that Bloomberg Intelligence sees up to $48 billion, 2nm ramp, US fab plans and memory-chip shortage commentary.
This Bloomberg Markets video, published January 15, 2026,
features Yvonne Man, Mark Cudmore, Tony Ho, Catherine Lim, Amber Tong, Laura Wang, Lulu Chen, Simon Loong, Annabel Droulers
discussing Beijing Stock Exchange, ECNS, FXY, USD/JPY, SILVER, EWH, ASHR, 1530.HK, TCOM, NVO, LLY, China AI, AI-SECTOR, China automation, China biotech, China smart manufacturing, China insurance sector, BABA, BIZD, TSM.
16 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Yvonne Man,
Mark Cudmore,
Tony Ho,
Catherine Lim,
Amber Tong,
Laura Wang,
Lulu Chen,
Simon Loong,
Annabel Droulers
· Tickers:
Beijing Stock Exchange,
ECNS,
FXY,
USD/JPY,
SILVER,
EWH,
ASHR,
1530.HK,
TCOM,
NVO,
LLY,
China AI,
AI-SECTOR,
China automation,
China biotech,
China smart manufacturing,
China insurance sector,
BABA,
BIZD,
TSM
